|
Mammary Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
However, no study has been dedicated to analyze the significance of microRNA-related SNP rs1972820, located in ERBB4 3'-untranslated region (UTR), in breast tumors.
|
28508829 |
2018 |
|
Mammary Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The growth factor heregulin (HRG), a ligand of ErbB3 and ErbB4 receptors, contributes to breast cancer development and the promotion of metastatic disease, and its expression in breast tumors has been associated with poor clinical outcome and resistance to therapy.
|
27185877 |
2016 |
|
Mammary Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
However, no study has been conducted to investigate the importance of rs11895168, a microRNA-related SNP located in ErbB4 3'UTR, in breast tumors.
|
27262100 |
2016 |
|
Mammary Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
An exon array analysis of 155 breast tumors revealed that the relative mRNA abundance of the ErbB4 CYT2 variant was increased in ER+ HER2- breast cancer patients, suggesting that our findings could be clinically relevant.
|
25140053 |
2014 |
|
Mammary Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
We verified HER4 promoter methylation in primary breast carcinomas and detected a significant increase in HER4 promoter methylation in HER4-negative breast tumors (P<0.001).
|
20603612 |
2010 |
|
Mammary Neoplasms
|
0.100 |
AlteredExpression
|
group |
LHGDN |
Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study.
|
18985033 |
2008 |
|
Mammary Neoplasms
|
0.100 |
AlteredExpression
|
group |
LHGDN |
Association of Wwox with ErbB4 in breast cancer.
|
17909041 |
2007 |
|
Mammary Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Activated ERBB4 has been demonstrated to induce cell killing of breast tumor cells.
|
16832345 |
2007 |
|
Mammary Neoplasms
|
0.100 |
Biomarker
|
group |
LHGDN |
Coregulation of estrogen receptor by ERBB4/HER4 establishes a growth-promoting autocrine signal in breast tumor cells.
|
16912174 |
2006 |
|
Mammary Neoplasms
|
0.100 |
AlteredExpression
|
group |
LHGDN |
Proteolytic cleavage and phosphorylation of a tumor-associated ErbB4 isoform promote ligand-independent survival and cancer cell growth.
|
16251361 |
2006 |
|
Mammary Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These data suggest that ErbB4 behaves as a mammary tumor suppressor and that loss of ErbB4 coupling to growth arrest may be an important event in mammary tumorigenesis.
|
17120616 |
2006 |
|
Mammary Neoplasms
|
0.100 |
Biomarker
|
group |
LHGDN |
HER4 in breast cancer: comparison of antibodies against intra- and extra-cellular domains of HER4.
|
16606438 |
2006 |
|
Mammary Neoplasms
|
0.100 |
AlteredExpression
|
group |
LHGDN |
Clinically, cytosolic but not membrane ERBB4/4ICD expression in primary human breast tumors was associated with tumor apoptosis, providing a mechanistic explanation for the loss of ERBB4 expression during tumor progression.
|
16778220 |
2006 |
|
Mammary Neoplasms
|
0.100 |
Biomarker
|
group |
LHGDN |
Heregulin-dependent delay in mitotic progression requires HER4 and BRCA1.
|
16914727 |
2006 |
|
Mammary Neoplasms
|
0.100 |
AlteredExpression
|
group |
LHGDN |
Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells.
|
15735025 |
2005 |
|
Mammary Neoplasms
|
0.100 |
Biomarker
|
group |
LHGDN |
Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling.
|
15084248 |
2004 |
|
Mammary Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Expression of both erbB-4 variants was found in 7/7 normal breast tissues but only in 9/12 breast tumours analysed.
|
9780009 |
1998 |